Chimeric Therapeutics (ASX:CHM) EV-to-EBIT : -0.55 (As of Jul. 22, 2025)

Chimeric Therapeutics EV-to-EBIT Chart

Competitive Comparison of Chimeric Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Chimeric Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's EV-to-EBIT falls into.

Chimeric Therapeutics EV-to-EBIT Calculation

Chimeric Therapeutics's EV-to-EBIT for today is calculated as:

Chimeric Therapeutics's current Enterprise Value is A$9.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-17.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics  (ASX:CHM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Chimeric Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Chimeric Therapeutics's Enterprise Value for the quarter that ended in Dec. 2024 was A$5.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-17.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics Business Description